Low Density Lipoprotein Apheresis in Pediatric Patients With Homozygous Familial Hypercholesterolemia
- 26 March 2009
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 13 (2) , 121-128
Abstract
The aim of the present study is to clarify the low density lipoprotein apheresis procedure for pediatric patients with homozygous familial hypercholesterolemia (FH) in terms of efficacy, adverse effects and difficulties. The follow‐up was carried out using an open, prospective uncontrolled clinical design. Data were collected from 10 patients (with an average age of 8.4 ± 4.7 years) with FH treated with double filtration plasmapheresis. The total time span of follow‐up covered five years (30.2 ± 17.8 months [range 9–60 months]) and more than 600 sessions (62.1 ± 35.5 sessions per patient [range 18–120 sessions]) were evaluated. The mean low density lipoprotein cholesterol (LDL‐C) pre‐treatment value was 375.5 ± 127.5 mg/dL, and the post‐treatment value was 147.5 ± 73.9 mg/dL. This corresponded to a 62.8 ± 10.3% (43–73%) acute reduction of LDL‐C, while the mean high density lipoprotein cholesterol losses amounted to 41%. The chronic reduction in LDL‐C ranged from 18 to 52%, with a mean level of 36.4 ± 11.7%. The most frequently occurring technical problems were related to blood lines: puncture difficulties (4.5%), insufficient blood flow (3.5%), and obturation of the blood lines (2.4%). The main clinical adverse effects were hypotension (0.2%), chills/feeling cold (0.1%), and nausea and vomiting (0.2%). We observed that the low pediatric patient tolerance is the main problem in compliance with treatment. In conclusion, LDL apheresis, started under the age of eight years, combined with lipid‐lowering drugs, provides a safe and effective lowering of the mean LDL‐C levels in pediatric homozygous FH; and there are more problems with compliance for pediatric LDL apheresis than in the adult population.Keywords
This publication has 12 references indexed in Scilit:
- Recommendations for the use of LDL apheresisAtherosclerosis, 2008
- Cardiovascular Risk Reduction in High-Risk Pediatric PatientsCirculation, 2006
- Direct Adsorption of Low‐Density Lipoprotein by DALI‐LDL‐Apheresis: Results of a Prospective Long‐term Multicenter Follow‐up Covering 12 291 SessionsTherapeutic Apheresis and Dialysis, 2006
- Direct Adsorption of Lipoproteins from Whole Blood by Direct Adsorption of Lipoprotein Apheresis: First Experience in Two Hypercholesterolemic ChildrenTherapeutic Apheresis and Dialysis, 2005
- Long-Term Effects of Low-Density Lipoprotein Apheresis Using an Automated Dextran Sulfate Cellulose Adsorption System fn1fn1This study was supported by a grant from the Kaneka America Corporation, New York, New York.The American Journal of Cardiology, 1998
- Low-Density Lipoprotein Apheresis Versus Lipid Lowering Drugs in the Treatment of Severe Hypercholesterolemia: Four Years' ExperienceArtificial Organs, 1996
- Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemiaThe Journal of Pediatrics, 1995
- Progression and regression of coronary artery diseaseCurrent Opinion in Lipidology, 1992
- Treatment of children with homozygous familial hypercholesterolemia: Safety and efficacy of low-density lipoprotein apheresisThe Journal of Pediatrics, 1992
- Xanthomas and hyperlipidemiasJournal of the American Academy of Dermatology, 1985